Mersana Dolaflexin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mersana dolaflexin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mersana Dolaflexin Today - Breaking & Trending Today

Mersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer


Mersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer
April 26, 2021 08:00 ET
| Source:
Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc.
Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer.
“With our UPLIFT strategy now underway for UpRi and our growing pipeline of product candidates derived from our innovative ADC platforms, we are thrilled to have Alejandra join the team at this time of immense growth,” said Anna Protopapas, President and Chief Executive Officer of Mersana ....

United Kingdom , Hill Barlow , Mersana Dolaflexin , Anna Protopapas , Momenta Pharmaceuticals , Georgetown University Law Center , Mersana Therapeutics Inc , Berry Howard , Millennium Pharmaceuticals , Harvard University , Company Immunosynthen , Alejandra Carvajal , Senior Vice President , Chief Legal , Chief Executive Officer , Chief Legal Officer , General Counsel , Vice President , Juris Doctorate , Nasdaq Mrsn , Mersana Therapeutics , ஒன்றுபட்டது கிஂக்டம் , மலை பார்லோ , ஜார்ஜ்டவுன் பல்கலைக்கழகம் சட்டம் மையம் , பெர்ரி ஹோவர்ட் , மில்லினியம் மருந்துகள் ,

Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors


Published: Mar 11, 2021
CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) Mersana Therapeutics, Inc.. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Allene Diaz to its board of directors.
“Allene’s breadth of knowledge in strategic product planning, portfolio management and commercialization of cancer therapeutics will be invaluable to Mersana as we focus on building UpRi as a foundational therapy for the treatment of ovarian cancer and building out our maturing pipeline of ADC candidates. With our growing portfolio of product candidates, the strategic choices we make to create differentiated product labeling and positioning are critical to our vision of discovering and developing life-changing ADC therapies for patients fighting cancer. We are excited to benefit from Allene’s ....

United Kingdom , Sarah Carmody , Mersana Dolaflexin , Anna Protopapas , Allene Diaz , Florida State University , Cancervax Corporation , Allena Pharmaceuticals , Acquisition Corporation , Mersana Therapeutics Inc , Exchange Commission , Company Annual Report On Form , Merck Kga , Parke Davis Pharmaceuticals , Company Immunosynthen , Merck Kgaa , Chief Executive Officer , Senior Vice President , Florida State , Annual Report , Mersana Therapeutics Announces Appointment Of Allene Diaz To Board Directors , ஒன்றுபட்டது கிஂக்டம் , சாரா கார்மோடி , அல்லீன் டியாஸ் , புளோரிடா நிலை பல்கலைக்கழகம் , அலெனா மருந்துகள் ,